Literature DB >> 9677705

Molecular genetics of the hereditary ataxias.

M Pandolfo1, L Montermini.   

Abstract

One of us (MP) learned about the mapping of Huntington disease gene to chromosome 4 from the late Dr. Anita Harding. She got the news over the phone from her London office during a visit to Italy for a meeting on hereditary ataxias. In Britain, they receive Nature at least a week earlier than us. Dr. Harding was very excited, and she immediately said that that was the way to go if we wanted to understand the causes of hereditary ataxias, classify these diseases in a rational way, and eventually find a treatment. At that time, the challenge seemed, and indeed was, formidable. No clue was then available about the genetic basis of what Dr. Harding aptly called "hereditary ataxias of unknown cause," their classification was confused and controversial, and all attempts to find specific biochemical abnormalities had failed. Fourteen years later, the success of the molecular genetic studies is astounding. The defective genes have been identified for Friedreich ataxia, the major recessive "hereditary ataxia of unknown cause," and for five dominantly inherited "hereditary ataxias of unknown cause." Three more dominant ataxia genes have been mapped. The molecular pathogenesis of the dominant ataxias begins to be unraveled and animal models have been and are being developed. Information is also quickly accumulating about the defective protein in Friedreich ataxia. Direct molecular diagnosis is now possible. Classification has been revolutionized. Diagnostic criteria are being redefined in the light of the molecular discoveries. The goal of this review, dedicated to the memory of the late Dr. Harding, is to offer a concise summary of current knowledge about the molecular genetics of some of the hereditary ataxias that used to be classified as of "unknown cause."

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9677705     DOI: 10.1016/s0065-2660(08)60141-8

Source DB:  PubMed          Journal:  Adv Genet        ISSN: 0065-2660            Impact factor:   1.944


  3 in total

1.  Absence of aprataxin gene mutations in a Greek cohort with sporadic early onset ataxia and normal GAA triplets in frataxin gene.

Authors:  C Daiou; K Christodoulou; G Xiromerisiou; M Panas; E Dardiotis; A Kladi; M Speletas; G Ntaios; A Papadimitriou; A Germenis; Georgios M Hadjigeorgiou
Journal:  Neurol Sci       Date:  2009-12-02       Impact factor: 3.307

2.  Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design.

Authors:  Lisa S Friedman; Jennifer M Farmer; Susan Perlman; George Wilmot; Christopher M Gomez; Khalaf O Bushara; Katherine D Mathews; S H Subramony; Tetsuo Ashizawa; Laura J Balcer; Robert B Wilson; David R Lynch
Journal:  Mov Disord       Date:  2010-03-15       Impact factor: 10.338

3.  Clinical manifestations and gene mutation in a case of Machado-Joseph disease.

Authors:  Bin Zhang; Liru Li; Longxing Chen; Jie Huang
Journal:  Neural Regen Res       Date:  2012-12-15       Impact factor: 5.135

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.